Lytix Biopharma presents first half and second quarter 2023 results
OSLO, Norway, August 31 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its first half and second quarter 2023 results.
Chief Executive Officer of Lytix Biopharma, Dr. Øystein Rekdal, commented: “We have continued to make positive progress as we build a clinical Phase II evidence base for our lead compound LTX-315. Earlier this month we received strong data from Part 1 of Verrica Pharmaceuticals’ ongoing clinical Phase II study and more recently we announced the recruitment of all 20 patients into the ATLAS-IT-05 trial. Furthermore, today we announce that a second melanoma study will commence in 1H 2024, with LTX-315 being tested in combination with pembrolizumab in a neoadjuvant Phase II setting. Given this study will include patients with earlier stage disease, we expect to see an improvement in the response rates due to patients enrolled in this study having healthier immune system.”
